From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity . RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α . RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity .
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM.Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes.Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions.Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis .
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC50 values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .
SIRPA Human Pre-designed siRNA Set A contains three designed siRNAs for SIRPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis .
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC50 values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis .
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
Sirpa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirpa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47 +/B7-H3 + cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47 +/B7-H3 + tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer .
SHR-1603 is a humanized anti-CD47 IgG4 antibody. SHR-1603 blocks the interaction of CD47 with SIRPα and enhances phagocytosis. SHR-1603 includes active Fc domains to mediate CDC/ADCC functions. SHR-1603 can be used for the research of cancer [1][2].
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape .
Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC50 values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
Anzurstobart is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM.Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes.Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions.Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro .
Maplirpacept (TTI-622; PF-07901801) is a fusion protein consisting of the CD47-binding domain of human SIRPα linked to the Fc region of human IgG4. Maplirpacept enhances phagocytosis by blocking CD47 .
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets CD47. Gentulizumab displays strong binding to CD47 in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .
ES004 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a. ES004 enhances macrophage phagocytosis and induces potent T cell responses to promote tumor killing. ES004 can be used in Solid tumours research .
Moflerafusp alfa is a fusion protein targeting the human signal regulatory protein α (SIRPα) variant V2 D1 domain and human programmed death ligand 1 (PD-L1). Moflerafusp alfa is promising for research of various cancers .
IBI-397 is a human monoclonal antibody (mAb) targeting SIRPα/CD172a . IBI-397 promotes human monocyte-derived dendritic cell-mediated T cell proliferation and increases the expression of CD86 and HLA-DR. IBI-397 has antitumor activity in the mouse MDA-MB-231 tumor model. IBI-397 can be used in Myeloma research .
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .
VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47 +/B7-H3 + cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47 +/B7-H3 + tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer .
SHR-1603 is a humanized anti-CD47 IgG4 antibody. SHR-1603 blocks the interaction of CD47 with SIRPα and enhances phagocytosis. SHR-1603 includes active Fc domains to mediate CDC/ADCC functions. SHR-1603 can be used for the research of cancer [1][2].
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
SIRP-beta (Sirpb, CD172b) is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP family members are receptor-type transmembrane glycoproteins, Sirpb was found to interact with TYROBP/DAP12, a transmembrane adaptor protein bearing immunoreceptor tyrosine-based activation motifs, resulting in the tyrosine phosphorylation of DAP12 and the subsequent recruitment of Syk to the Sirpb-DAP12 complex. Sirpb is also implicated as a positive regulator of hematopoietic cells. SIRP beta Protein, Mouse (HEK293, His) is the recombinant mouse-derived SIRP beta protein, expressed by HEK293 , with C-His labeled tag.
SIRP γ protein is a possible immunoglobulin-like cell surface receptor that mediates cell-cell adhesion by binding to CD47. This interaction enhances antigen-specific T cell proliferation and provides costimulatory signals for T cell activation, highlighting the role of SIRP gamma in regulating immune responses. SIRP gamma Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP gamma protein, expressed by HEK293 , with C-His, C-Avi labeled tag.
SIRP γ protein is a possible immunoglobulin-like cell surface receptor that mediates cell-cell adhesion by binding to CD47. This interaction enhances antigen-specific T cell proliferation and provides costimulatory signals for T cell activation, highlighting the role of SIRP gamma in regulating immune responses. SIRP gamma Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP gamma protein, expressed by HEK293 , with C-His, C-Avi labeled tag.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane.It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment.SIRP alpha/CD172a Protein, Mouse (HEK293, His) is the recombinant mouse-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-6*His labeled tag.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-6*His labeled tag.
When paired with KLRD1, the NKG2C/CD159c protein recognizes MHC-E loaded with MHC-G peptides, thereby contributing to NK cell generation and function. It also regulates cytotoxic lymphocytes in viral infections. SIRP alpha/CD172a Protein, Rat (HEK293, His) is the recombinant rat-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-His labeled tag.
When paired with KLRD1, the NKG2C/CD159c protein recognizes MHC-E loaded with MHC-G peptides, thereby contributing to NK cell generation and function. It also regulates cytotoxic lymphocytes in viral infections. SIRP alpha/CD172a Protein, Rat (HEK293, Fc) is the recombinant rat-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-hFc labeled tag.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane.It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment.SIRP alpha/CD172a Protein, Mouse (BAA20376, HEK293, Fc) is the recombinant mouse-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-hFc labeled tag.
Signal-Regulatory Protein Gamma; SIRP-Gamma; CD172 Antigen-Like Family Member B; Signal-Fegulatory Protein Beta-2; SIRP-b2; SIRP-Beta-2; CD172g; SIRPG; SIRPB2
SIRP γ protein is a possible immunoglobulin-like cell surface receptor that mediates cell-cell adhesion by binding to CD47. This interaction enhances antigen-specific T cell proliferation and provides costimulatory signals for T cell activation, highlighting the role of SIRP gamma in regulating immune responses. SIRP gamma Protein, Human (HEK293, Fc) is the recombinant human-derived SIRP gamma protein, expressed by HEK293 , with C-hFc labeled tag.
SIRP beta 1 protein negatively regulates receptor tyrosine kinase signaling and recruits SYK for myeloid cell activation. It interacts with TYROBP as a homodimer, facilitating SYK recruitment. This intricate molecular interplay is crucial for modulating myeloid cell activation and regulating cellular signaling. SIRP beta 1 occupies a central position in protein interactions that contribute to its functional role. SIRP beta 1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP Beta 1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
SIRP alpha V8/CD172a Protein, Human (AAH38510, HEK293, His) is the recombinant human-derived SIRP alpha V8/CD172a protein, expressed by HEK293, with C-His labeled tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha/CD172a Protein, Human (G75A, HEK293, His) is the recombinant human-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-His labeled tag and G75A, , , , mutation.
SIRP alpha V8/CD172a Protein, Human (AAH38510, HEK293, Fc) is the recombinant human-derived SIRP alpha V8/CD172a protein, expressed by HEK293, with C-mFc labeled tag.
SIRP alpha V2/CD172a Protein, Human (HEK293, His) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-His labeled tag.
SIRP alpha V2/CD172a Protein, Human (HEK293, Fc) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-hFc labeled tag.
SIRP beta 1 protein negatively regulates receptor tyrosine kinase signaling and recruits SYK for myeloid cell activation. It interacts with TYROBP as a homodimer, facilitating SYK recruitment. This intricate molecular interplay is crucial for modulating myeloid cell activation and regulating cellular signaling. SIRP beta 1 occupies a central position in protein interactions that contribute to its functional role. SIRP beta 1 Protein, Human (Biotinylated, HEK293, C-His-Avi) is the recombinant human-derived SIRP Beta 1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha/CD172a Protein, Human (Biotinylated, HEK293, Fc-Avi) is the recombinant human-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-Avi, C-hFc labeled tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V4/CD172a Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP alpha V4/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and E33G, L44S, T50S, T52I, R54H mutation.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V4/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V4/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and E33G, L44S, T50S, T52I, R54H mutation.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V6/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V6/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and S105P, , , , mutation.
SIRP alpha V2/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V2/CD172a protein, expressed by HEK293, with C-Avi, C-His labeled tag.
SIRP alpha V3 Protein, Human (H54L, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V3 protein, expressed by HEK293, with C-Avi, C-His labeled tag.
SIRP alpha V3 Protein, Human (Biotinylated, H54L, HEK293, His-Avi) is the recombinant human-derived SIRP alpha V3 protein, expressed by HEK293, with C-Avi, C-His labeled tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V6/CD172a Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP alpha V6/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag and S105P, , , , mutation.
SIRP gamma Protein, a member of signal-regulatory protein (SIRP) family, is the only SIRP detected on T cells and activated NK cells. SIRP gamma can bind CD47, providing T cells and NK cells with a cell surface molecule capable of interacting with CD47. SIRP gamma-CD47 interaction mediates strong cell-cell adhesion and supports T cell-APC contact, enhancing antigen presentation and consequent T-cell proliferation and cytokine secretion. SIRP gamma Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived SIRP gamma protein, expressed by HEK293 , with C-His labeled tag.
SIRP gamma Protein, a member of signal-regulatory protein (SIRP) family, is the only SIRP detected on T cells and activated NK cells. SIRP gamma can bind CD47, providing T cells and NK cells with a cell surface molecule capable of interacting with CD47. SIRP gamma-CD47 interaction mediates strong cell-cell adhesion and supports T cell-APC contact, enhancing antigen presentation and consequent T-cell proliferation and cytokine secretion. SIRP gamma Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived SIRP gamma protein, expressed by HEK293 , with C-hFc labeled tag.
SIRP beta 2 Protein, a novel positive regulator of innate immunotherapy, is a member of the signal-regulatory-protein (SIRP) family, and also belongs to the immunoglobulin superfamily. SIRP beta 2 is expressed on myeloid cells at protein level and enhanced adhesion, differentiation, cancer cell phagocytosis and T cell activation in an in vitro setting. DAP12 is responsible for SIRP beta 2 signaling, and is recruited through a single, positive lysine residue in the transmembrane domain of SIRP beta 2. SIRP beta 2 Protein, Human (HEK293, Fc) is the recombinant human-derived SIRP beta 2 protein, expressed by HEK293 , with C-hFc labeled tag.
SIRP beta 1 protein negatively regulates receptor tyrosine kinase signaling and recruits SYK for myeloid cell activation. It interacts with TYROBP as a homodimer, facilitating SYK recruitment. This intricate molecular interplay is crucial for modulating myeloid cell activation and regulating cellular signaling. SIRP beta 1 occupies a central position in protein interactions that contribute to its functional role. SIRP beta 1 Protein, Human (HEK293, His) is the recombinant human-derived SIRP beta 1 protein, expressed by HEK293 , with C-6*His labeled tag.
SIRP beta 1 protein negatively regulates receptor tyrosine kinase signaling and recruits SYK for myeloid cell activation. It interacts with TYROBP as a homodimer, facilitating SYK recruitment. This intricate molecular interplay is crucial for modulating myeloid cell activation and regulating cellular signaling. SIRP beta 1 occupies a central position in protein interactions that contribute to its functional role. SIRP beta 1 Protein, Human (HEK293, hFc) is the recombinant human-derived SIRP beta 1 protein, expressed by HEK293, with C-hFc labeled tag.
SIRP beta 1 protein negatively regulates receptor tyrosine kinase signaling and recruits SYK for myeloid cell activation. It interacts with TYROBP as a homodimer, facilitating SYK recruitment. This intricate molecular interplay is crucial for modulating myeloid cell activation and regulating cellular signaling. SIRP beta 1 occupies a central position in protein interactions that contribute to its functional role. SIRP beta 1 Protein, Human (HEK293, His-Myc) is the recombinant human-derived SIRP beta 1 protein, expressed by HEK293 , with N-6*His, N-Myc labeled tag.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-hFc labeled tag. The total length of SIRP alpha/CD172a Protein, Cynomolgus (HEK293, Fc) is 340 a.a., with molecular weight of 70-85 kDa.
SIRP alpha/CD172a Protein, Human (P78324, HEK293, Fc) produced in HEK293 cells with the C-termimal human IgG1 Fc fragment. Signal regulatory protein alpha (SIRPα, designated CD172a) is a monomeric about 90kDa type I transmembrane glycoprotein that belongs to the SIRP/SHPS (CD172) family of the immunoglobulin superfamily.
SIRP alpha/CD172a Protein, Human (P78324, HEK293, His) is a polypeptide chain amino acids with the C-termimal His tag. Signal regulatory protein alpha (SIRPα, designated CD172a) is a monomeric about 90kDa type I transmembrane glycoprotein that belongs to the SIRP/SHPS (CD172) family of the immunoglobulin superfamily.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
SIRP alphaV8/CD172a Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP alphaV8/CD172a protein, expressed by HEK293, with C-Avi, C-His labeled tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. PE-Labeled SIRP alpha/CD172a Protein, Human (HEK293, Fc) is the recombinant human-derived PE-Labeled SIRP alpha/CD172a protein, expressed by HEK293 , with Fc labeled tag.
The SIRP α/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 and is essential for the translocation of binding partners to the plasma membrane. It plays a key role in a variety of cellular processes, supporting the adhesion of cerebellar neurons, promoting neurite outgrowth, and promoting glial cell attachment. SIRP alpha/CD172a Protein, Mouse (G365D, HEK293, mFc) is the recombinant mouse-derived SIRP alpha/CD172a protein, expressed by HEK293 , with C-mFc labeled tag and G365D, , , , mutation. The total length of SIRP alpha/CD172a Protein, Mouse (G365D, HEK293, mFc) is 342 a.a., with molecular weight of 90-130 kDa.
SIRP alpha/CD172a Protein, Human (CAA71403.1, HEK 293, His)
, as a recombinant protein produced in HEK293 cells, is a polypeptide chain with a His tag.
The SIRP α V4/CD172a protein is an immunoglobulin-like cell surface receptor for CD47 that acts as a docking protein to facilitate the translocation of PTPN6, PTPN11, and other partners to the plasma membrane. It supports the adhesion of cerebellar neurons, promotes neurite growth, and promotes glial cell attachment. SIRP alpha V5/CD172a Protein, Human (HEK293, His, Avi) is the recombinant human-derived SIRP alpha V5/CD172a protein, expressed by HEK293, with C-His and C-Avi labeled tag.
SIRPA Human Pre-designed siRNA Set A contains three designed siRNAs for SIRPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Sirpa Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirpa gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
